2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-16637R
    Folic acid (Standard) 59-30-3 98.39%
    Folic acid (Standard) is the analytical standard of Folic acid. This product is intended for research and analytical applications. Folic acid (Vitamin B9) is a orally active essential nutrient from the B complex group of vitamins. Folic acid shows antidepressant-like effect. Folic acid sodium reduces the risk of neonatal neural tube defects. Folic acid can be used to the research of megaloblastic and macrocytic anemias due to folic deficiency.
    Folic acid (Standard)
  • HY-B0215A
    Acetylcysteine (extracted from plants) 616-91-1 100.45%
    Acetylcysteine (N-Acetylcysteine) extracted from plants is derived from plants and is an antioxidant and mucolytic agent that enhances the reserve of free radical scavengers in cells. It has been reported to prevent neuronal apoptosis while inducing apoptosis in smooth muscle cells. In addition, it inhibits HIV replication and serves as a substrate for microsomal glutathione transferase. This endogenous aminothiol is found in human plasma and urine and is commonly used as a mucolytic agent in clinical settings, usually administered by inhalation.
    Acetylcysteine (extracted from plants)
  • HY-B0282R
    Acetylcholine chloride (Standard) 60-31-1
    Acetylcholine (chloride) (Standard) is the analytical standard of Acetylcholine (chloride). This product is intended for research and analytical applications. Acetylcholine chloride (ACh chloride), a neurotransmitter, is a potent cholinergic agonist. Acetylcholine chloride is a modulator of the activity of dopaminergic (DAergic) neurons through the stimulation of nicotinic acetylcholine receptors (nAChRs). Acetylcholine chloride inhibits p53 mutant peptide aggregation in vitro.
    Acetylcholine chloride (Standard)
  • HY-N2368A
    Arecaidine hydrochloride 6018-28-6
    Arecaidine hydrochloride, a pyridine alkaloid, is a potent GABA uptake inhibitor. Arecaidine hydrochloride is a substrate of H+-coupled amino acid transporter 1 (PAT1, SLC36A1) and competitively inhibits L-proline uptake.
    Arecaidine hydrochloride
  • HY-P1218B
    Phrixotoxin 3-NH2 TFA 98.63%
    Phrixotoxin 3-NH2 TFA is a derivative of Phrixotoxin 3 TFA (HY-P1218A). Phrixotoxin 3 TFA is a potent blocker of voltage-gated sodium channels, with IC50s of 0.6, 42, 72, 288, 610 nM for NaV1.2, NaV1.3, NaV1.4, NaV1.1 and NaV1.5, respectively. Phrixotoxin 3 TFA modulates voltage-gated sodium channels with properties similar to those of typical gating-modifier toxins, both by causing a depolarizing shift in gating kinetics and by blocking the inward component of the sodium current.
    Phrixotoxin 3-NH2 TFA
  • HY-121883S
    Lignoceric acid-d47 68060-00-4 98.4%
    Lignoceric acid-d47 is the deuterium labeled Lignoceric acid. Lignoceric acid (Tetracosanoic acid) is a 24-carbon saturated (24:0) fatty acid, which is synthesized in the developing brain. Lignoceric acid is also a by-product of lignin production. Lignoceric acid can be used for Zellweger cerebro‐hepato‐renal syndrome and adrenoleukodystrophy research.
    Lignoceric acid-d47
  • HY-W012998
    2,3-Pentanedione 600-14-6
    2,3-Pentanedione is a common constituent of synthetic flavorings and is used to impart a butter, strawberry, caramel, fruit, rum, or cheese flavor in beverages, ice cream, candy, baked goods, gelatins, and puddings. 2,3-Pentanedione also occurs naturally as a fermentation product in beer, wine, and yogurt and is releasedduring roasting of coffee beans.
    2,3-Pentanedione
  • HY-W040150
    (24S,25)-Epoxycholesterol 77058-74-3 98.10%
    24S,25-Epoxycholesterol is an agonist for Liver X Receptor (LXR). 24S,25-Epoxycholesterol exhibits properties in regulating the cholesterol efflux, inhibiting tumor growth against gastric cancer and glioblastoma and inducing apoptosis in BMMC cells.
    (24S,25)-Epoxycholesterol
  • HY-W096171
    D-Dopa 5796-17-8 98%
    D-Dopa is a non-competitive, allosteric inhibitor for glutamate carboxypeptidase II (GCPII) with an IC50 of 200 nM. D-Dopa exhibits good pharmacokinetic characteristics, and low blood-brain barrier permeability in mouse model.
    D-Dopa
  • HY-W761299
    PD 4'-oxyacetic acid 2633633-12-0 99.69%
    PD 4'-oxyacetic acid is a carboxylic acid-functionalized cereblon ligand that can be used for PROTAC Degrader development.
    PD 4'-oxyacetic acid
  • HY-W096638A
    Glycerophosphocholine 4217-84-9 98.89%
    Glycerophosphocholine ((S)-Glycerolphosphocholine) is an intracellular metabolite during phosphatidylcholine metabolism and can be used to study the endogenous choline supply of cells. Glycerophosphocholine is used as a supplement in research into brain disorders.
    Glycerophosphocholine
  • HY-119980
    Fluphenazine 69-23-8 98.70%
    Fluphenazine is a potent, orally active phenothiazine-based dopamine receptor antagonist. Fluphenazine blocks neuronal voltage-gated sodium channels. Fluphenazine acts primarily through antagonism of postsynaptic dopamine-2 receptors in mesolimbic, nigrostriatal, and tuberoinfundibular neural pathways. Fluphenazine can antagonize Methylphenidate-induced stereotyped gnawing and inhibit climbing behaviour in mice. Fluphenazine can be used for researching psychosis and painful peripheral neuropathy associated with diabetes and has potential to inhibit SARS-CoV-2.
    Fluphenazine
  • HY-15147G
    XAV-939 (GMP) 284028-89-3 98%
    XAV-939 (GMP) is XAV-939 (HY-15347) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. XAV-939 is a tankyrase inhibitor.
    XAV-939 (GMP)
  • HY-23196S
    Minoxidil-d10 1020718-66-4 99.96%
    Minoxidil-d10 (U10858-d10) is the deuterium labeled Minoxidil. Minoxidil (U10858) is an ATP-sensitive potassium (KATP) channel opener, a potent oral antihypertensive agent and a peripheral vasodilator that promotes vasodilation also affects hair growth. Minoxidil is also a potent inhibitor of soybean lipoxygenaseare with an IC50 of 20 μM[1][2][3].
    Minoxidil-d10
  • HY-B0590S
    Tetrabenazine-d6 1392826-25-3 ≥99.0%
    Tetrabenazine-d6 (Deutetrabenazine) is a deuterium-labled Tetrabenazine (HY-B0590), is the first deuterium approved worldwide for the research of Huntington's disease, or other hyperkinetic movement disorders.
    Tetrabenazine-d6
  • HY-N1424S
    Glycoursodeoxycholic Acid-d4 2044276-17-5 98.88%
    Glycoursodeoxycholic acid-d4 (Ursodeoxycholylglycine-d4) is the deuterium labeled Glycoursodeoxycholic acid. Glycoursodeoxycholic acid, a acyl glycine and a bile acid-glycine conjugate, is a metabolite of ursodeoxycholic acid.
    Glycoursodeoxycholic Acid-d4
  • HY-12150
    CCMI 917837-54-8 99.97%
    CCMI (AVL-3288) is a potent and selective α7 nAChR-positive allosteric modulator, does not bind to or activate α7 nAChRs via the orthosteric site, and causes significant positive modulation of agonist-induced currents at α7 nAChRs. CCMI has potential in CNS diseases with cognitive dysfunction.
    CCMI
  • HY-112157
    PF-06751979 1818339-66-0 99.23%
    PF-06751979 is a potent, brain penetrant, β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor with an IC50 of 7.3 nM in BACE1 binding assay.
    PF-06751979
  • HY-114403
    VU6012962 2313526-86-0 99.92%
    VU6012962 is an orally bioavailable and CNS-penetrant metabotropic glutamate receptor 7 negative allosteric modulator (mGlu7 NAM) with an IC50 of 347 nM.
    VU6012962
  • HY-116076
    S-15535 146998-34-7 99.82%
    S-15535 is a highly selective 5-HT1A receptor ligand. S-15535 is an antagonist of postsynaptic 5-HT1A receptors and an agonist of presynaptic 5-HT1A receptors. S-15535 can be used in research on psychiatric disorders, such as anti-anxiety.
    S-15535
Cat. No. Product Name / Synonyms Application Reactivity